SCHEMBL1320569

SCHEMBL1320569

Cc1cc(CCC2CCC2)on1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.40
S1PR3 Q99500 2/20 0.40
TSHR P16473 2/20 0.40
XBP1 P17861 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
VHL P40337 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
ALDH1A1 P00352 2/20 0.38
PDE10A Q9Y233 2/20 0.37
CHRNB2 P17787 3/20 0.37
CHRNB4 P30926 3/20 0.37
CHRNA3 P32297 3/20 0.37
CHRNA7 P36544 1/20 0.37
CHRNA4 P43681 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CHRNA5 P30532 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9863143 0.85 MEN1 (0.36) S1PR1S1PR3VHLMEN1KMT2A
SCHEMBL1320181 0.82 VHL (0.41) S1PR1S1PR3VHLMEN1KMT2A
SCHEMBL1320408 0.79 VHL (0.41) VHLMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL18256114 0.73 VHL (0.39) S1PR1S1PR3TSHRXBP1NPSR1
SCHEMBL805506 0.71
SCHEMBL14364098 0.71 NPC1 (0.49) S1PR1S1PR3TSHRXBP1NPSR1
SCHEMBL7938671 0.71 EPHX2 (0.44) S1PR1S1PR3TSHRXBP1NPSR1
SCHEMBL12384314 0.71 MEN1 (0.43) VHLMEN1KMT2AALDH1A1PDE10A
SCHEMBL1233711 0.70
SCHEMBL28037973 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058447-B2 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-11-15 US disclosed
EP-1926727-B1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF Bayer Pharma AG (DE) 2011-09-14 EP disclosed
US-7989633-B2 4-Chromenonyl-1,4-dihydropyridines and their use BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-02 US disclosed
US-20100022484-A1 4-Chromenonyl-1,4-dihydropyridines and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2010-01-28 US disclosed
US-20090214675-A1 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof BAYER HEALTHCARE AG (DE) 2009-08-27 US disclosed
EP-1926727-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF Bayer HealthCare AG (DE) 2008-06-04 EP disclosed
EP-1910329-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE Bayer HealthCare AG (DE) 2008-04-16 EP disclosed
WO-2007025604-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE BAYER HEALTHCARE AG (DE) 2007-03-08 WO disclosed
WO-2007009670-A1 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022484-A1 4-Chromenonyl-1,4-dihydropyridines and their use RYR1, RYR2, CACNA1S S1PR1 1937/4885S1PR3 2205/4885TSHR 3957/4885
US-20090214675-A1 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof RYR1, TNNI3, RYR2 S1PR1 3555/4885S1PR3 3983/4885TSHR 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.